| 1 |
You only need a DNA sequence
- no protein needed at any time |
| |
From gene to antibody without isolating
the target protein allows validation of hypothetical proteins.
|
| |
|
| 2 |
You need antibodies for target
validation, diagnostics, and therapy - we deliver antibodies
that recognize the native proteins |
| |
In vivo antigen expression and screening on mammalian
cells. |
| |
|
| |
GENOVAC antibodies are best
suited for native proteins |
| |
|
|
|
|
| |
|
| |
GENOVAC technology allows rapid
generation of high quality antisera for target screening |
| |
|
| |
Customer testing of polyclonal rat antisera by dilution
ELISA (human RAS still detectable at 1:500,000 serum
dilution) |
 |
 |
|
| |
|
| |
|
GENOVAC testing of polyclonal rat anti-human RAS
anitsera by flow cytomery (human RAS reveals 98%
sequence identity with rat orthologue)
yellow: pre-immune serum on transfected
cells
blue: immune serum on transfected cells
|
|
 |
|
| |
|
| 3 |
You have a whole set of genes
- we can generate antibodies in parallel |
| |
Parallel processing is time saving and
leads to dramatic cost and price reductions per target. |
| |
|
| 4
|
You want antibodies against
a GPCR - we are successful where others fail |
| |
Broad experience with refined application
of our technology allows the generation of antibodies
against difficult proteins. |
|
|
|
| |
GENOVAC technology allows antibody
development against 7-membrane-spanning GPCR proteins |
| |
|
|
|
|
GENOVAC testing of anti-GPCR monoclonal antibody
by flow cytometry
yellow: hybridoma supernatant binding
to mock-transfected cells
blue: hybridoma supernatant binding to GPCR-transfected
cells
|
|
 |
|
| |
|
| |
|
Customer testing of anti-GPCR monoclonal antibody
by immuno-fluorescence
HEK cells transfected with GPCR
blue staining - cell nuclei
green staining - GPCR fluorescence
|
|
 |
|
| |
|
| |
|
Customer testing of modulation of function using
GPCR transfectants
red: hybridoma supernatant
yellow: isotype control antibody
|
|
 |
|
| |
|
| |
Reference: Elagoz et al.: A truncated form
of CK{beta}8-1 is a potent agonist for human formly peptide-receptor-like
1 receptor. Br J Pharmacol.
2004 Jan, 141(1): 37-46 |
| |
|
| 5 |
You wish to modulate a protein's
function - we can focus against functional domains |
| |
Starting with DNA allows optimal design.
|
| |
|
| 6 |
You want to avoid risks - our
quality control minimizes your costs |
| |
Fee-for-service based on completion of
milestones. |
